Lyell Immunopharma, Inc.·4

Nov 12, 8:36 PM ET

Seely Lynn 4

4 · Lyell Immunopharma, Inc. · Filed Nov 12, 2025

Insider Transaction Report

Form 4
Period: 2025-11-10
Seely Lynn
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2025-11-10$16.11/sh412$6,63767,159 total
Footnotes (1)
  • [F1]Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

Documents

1 file
  • 4
    form4-11132025_011139.xmlPrimary